Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.74 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9660784 | 0.93 | TAAR1 (0.65) | TAAR1IDO1AGXTMAOBTDP1 | |
| SCHEMBL5240585 | 0.90 | TAAR1 (0.68) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL19524669 | 0.87 | TAAR1 (0.65) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL705920 | 0.87 | TAAR1 (0.65) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL30688447 | 0.87 | TAAR1 (0.65) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL235748 | 0.85 | TAAR1 (1.00) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL7199505 | 0.85 | TAAR1 (0.69) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL8733202 | 0.85 | TAAR1 (0.63) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL1513555 | 0.85 | TAAR1 (0.63) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL6500358 | 0.85 | TAAR1 (0.63) | TAAR1IDO1AGXTMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20070100180-A1 | Stilbene derivative, light emitting element material, light emitting element, light emitting device and electronic appliance | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| US-20070100180-A1 | Stilbene derivative, light emitting element material, light emitting element, light emitting device and electronic appliance | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| EP-1109545-A4 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | TAAR1 766/4885IDO1 794/4885AGXT 2158/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | TAAR1 1336/4885IDO1 1661/4885AGXT 4699/4885 |
| US-20070100180-A1 | Stilbene derivative, light emitting element material, light emitting element, light emitting device and electronic appliance | TLL1, MT-ATP8, TLL2 | TAAR1 3082/4885IDO1 3950/4885AGXT 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.